Similar Articles
How do COVID-19 vaccines affect rheumatic diseases?
Lale Altan, Salim Mısırcı, İlker Yağcı, Meltem Karacaatlı, Feyza Ünlü Özkan, Altuğ Güner, İlknur Aktaş
DOI: 10.46497/ArchRheumatol.2023.9530
Issue: Volume 38 - Issue 1 - March 2023
1022
1056
Efficacy of coronavirus disease 2019 vaccines in patients with rheumatic diseases
Fatih Taştekin, Meltem Taşbakan, Candan Çiçek, Mehmet Soylu, Figen Yargucu Zihni
DOI: 10.46497/ArchRheumatol.2023.9676
Issue: Volume 38 - Issue 3 - September 2023
771
766
Progressive pulmonary fibrosis in patients with connective tissue disease-associated interstitial lung disease: An explorative study
Jakob Höppner, Maximilian Wollsching-Strobel, Falk Schumacher, Wolfram Windisch, Melanie Berger
DOI: 10.46497/ArchRheumatol.2024.10105
Issue: Volume 39 - Issue 1 - March 2024
667
668
Predictive risk factors for one-year mortality in idiopathic inflammatory myopathy patients with interstitial lung disease: A retrospective, single-center cohort study
Minna Jiang, Xiaohong Wen, Sisi Xia, Yiqun Guo, Yu Bai
DOI: 10.46497/ArchRheumatol.2024.10418
Issue: Volume 39 - Issue 2 - June 2024
412
344
Rituximab for rheumatoid arthritis-related interstitial lung disease: A systematic review and meta-analysis
Tarun Krishna Boppana, Saurabh Mittal, Karan Madan, Anant Mohan, Vijay Hadda, Randeep Guleria
DOI: 10.46497/ArchRheumatol.2024.10199
Issue: Volume 39 - Issue 2 - June 2024
809
676